Thermo Fisher Scientific Inc (TMO) is listed on NYSE in the Healthcare sector Β· Diagnostics & Research industry. The current price is 610.82, up 0.37% from the previous close. Market cap is approximately $225.8B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
A P/E of 32.91x reflects strong expectations for future earnings growth. Multiple compression often starts the first quarter growth decelerates.
TMO's ROE of 13.51% is average. In this band, consistency and stability matter more than the absolute number.
Thermo Fisher Scientific Inc's elevated D/E of 80.58 either reflects an aggressive growth-via-debt strategy or balance sheet stress. Operating cash flow trend is the cleanest tell.
Thermo Fisher Scientific Inc's 10.50% revenue growth signals strong momentum. The quality (price vs volume, new vs existing customers) determines whether it is sustainable.
Thermo Fisher Scientific Inc's 0.31% yield falls short of typical income-investor thresholds. A consistent double-digit dividend growth rate can still compound meaningfully over time.
Clinical trial outcomes, FDA decisions, and drug-pricing policy drive most of the short-term volatility.
Thermo Fisher Scientific Inc is near its 52-week high (647.00), in the top 17% of the range. Prices close to new highs invite two readings β little overhead supply, or stretched expectations β and volume is the usual tiebreaker.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
The day's high-to-low spread reached 3.21%, with a 0.37% move. Wide sessions frequently follow earnings, filings, or sector news, so identifying the catalyst matters.
Thermo Fisher Scientific Inc (TMO) is listed on NYSE, with recent volume of 684,538 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.